Novavax (MEX:NVAX) Total Liabilities: MXN21,421 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:NVAX Novavax Inc MEX:NVAX
45 GF Score
Price MXN142.63
GF Value MXN66.19
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Novavax Total Liabilities?

Novavax MEX:NVAX 45 Total Liabilities is MXN21,421 Mil as of Mar. 2026. GuruFocus rates MEX:NVAX with a GF Score™ of 45/100 and a GF Value™ of MXN66.19 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Novavax's Total Liabilities for the quarter that ended in Mar. 2026 was MXN21,421 Mil.

Novavax's quarterly Total Liabilities declined from Sep. 2025 (MXN24,518.14 Mil) to Dec. 2025 (MXN23,484.20 Mil) and declined from Dec. 2025 (MXN23,484.20 Mil) to Mar. 2026 (MXN21,421.48 Mil).

Novavax's annual Total Liabilities increased from Dec. 2023 (MXN42,680.34 Mil) to Dec. 2024 (MXN45,554.25 Mil) but then declined from Dec. 2024 (MXN45,554.25 Mil) to Dec. 2025 (MXN23,484.20 Mil).

Novavax Total Liabilities Historical Data

* Premium members only.

The historical data trend for Novavax's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Novavax Total Liabilities Chart

Novavax Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 60,073.73 56,397.19 42,680.34 45,554.25 23,484.20

Novavax Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 27,999.81 24,457.70 24,518.14 23,484.20 21,421.48
MEX:NVAX
45GF Score
Novavax Inc MEX:NVAX
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Novavax Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Novavax's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=8281.722+(4434.876+4304.586
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+6463.02+0+0)
=23,484

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=21183.922--2300.282
=23,484

Novavax's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=6175.496+(5282.607+3484.712
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+6478.662+0+0)
=21,421

Total Liabilities=Total Assets (Q: Mar. 2026 )-Total Equity (Q: Mar. 2026 )
=18811.027--2610.45
=21,421

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of MXN21,421 Mil mean?
Novavax (MEX:NVAX) has a Total Liabilities of MXN21,421 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Novavax and its competitors.
Is Novavax's Total Liabilities too high?
Novavax's current Total Liabilities is MXN21,421 Mil. Overall, Novavax has a GF Score™ of 45/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Novavax's Total Liabilities compare to MPLT and COAG?
Novavax's Total Liabilities of MXN21,421 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Novavax and its competitors. Novavax's current Total Liabilities is MXN21,421 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novavax stock overvalued right now?
Based on GuruFocus' analysis, Novavax (MEX:NVAX) is currently considered Significantly Overvalued. The stock's GF Value™ is MXN66.19, compared to a current price of MXN142.63 — trading 115.5% above its estimated fair value. The current Total Liabilities is MXN21,421 Mil. Novavax's overall GF Score™ is 45/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Novavax (MEX:NVAX), the current Total Liabilities is MXN21,421 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Novavax (MEX:NVAX) Overvalued in 2026?

Based on GuruFocus' analysis, Novavax stock appears to be overvalued. The current stock price of MXN142.63 is trading 115.5% above its estimated GF Value™ of MXN66.19. GuruFocus considers Novavax to be Significantly Overvalued.

Key valuation signals for MEX:NVAX:

  • Total Liabilities: MXN21,421 Mil
  • GF Value™: MXN66.19 vs. price of MXN142.63 (115.5% above fair value)
  • GF Score™: 45/100 with 7 warning signs

No single metric tells the full story. See the MEX:NVAX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Novavax Business Description

Address 21 Firstfield Road, Gaithersburg, MD, USA, 20878
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.
45GF Score

Get the complete analysis for MEX:NVAX

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN142.63
Price
MXN66.19
GF Value